Previous 10 | Next 10 |
SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an ...
SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biopharmaceutical...
If you're interested in biotech stocks , you're not alone. The SPDR S&P Biotech ETF has outperformed the S&P 500 in eight of the past 10 years, so the industry has been a great source of market-beating ideas. Biotech investing isn't easy, though. Clinical-trial failures, expirin...
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
Company Overview Adaptimmune ( ADAP ) is a clinical-stage biotechnology company developing novel cell therapies in solid tumors. With their proprietary Specific Peptide Enhanced Affinity Receptor ("SPEAR") T cell platform, they identify cancer targets, find and genetically engineer T cell ...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) gained over 21% last month, according to data from S&P Global Market Intelligence . There wasn't any company-specific news to send the pharma stock higher. Well, not any new news, anyway. Investors continue to rally around...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities. More news on: Allogene Therapeutics, Inc., CorMedix, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
2020 should be another favorable year for healthcare investing, though the gains thus far in 2019 should necessitate greater selectivity. The overriding investment theme in healthcare, in my opinion, is the fact that the dual tailwinds of the aging of the population and the obesity epidemic (b...
Your immune system is constantly working to clean up faulty cells and damaged tissues. It's working, right now, to mop up pathogenic microbes and cancer cells before they can gain a foothold in your body. The search-and-destroy capabilities of immune cells have long made them ideal candidates fo...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...